Welcome to our dedicated page for Lineage Cell The news (Ticker: LCTX), a resource for investors and traders seeking the latest updates and insights on Lineage Cell The stock.
Lineage Cell Therapeutics, Inc. (Symbol: LCTX) is a clinical-stage biotechnology company that is pioneering the development and commercialization of novel therapies designed to address degenerative diseases. With a foundation built on pluripotent cell technology, Lineage Cell's innovative approach leverages cells capable of transforming into any type of cell in the human body. This groundbreaking capability allows for therapies aimed at regenerating or replacing damaged cells and tissues, providing hope for conditions that currently have no cure.
The company's pipeline is robust and diverse, encompassing several key product candidates:
- OpRegen: A retinal pigment epithelium transplant therapy targeting dry age-related macular degeneration, a leading cause of vision loss among the elderly.
- OPC1: An oligodendrocyte progenitor cell therapy designed to treat acute spinal cord injuries by promoting cell replacement and recovery.
- VAC2: An allogeneic cancer immunotherapy utilizing antigen-presenting dendritic cells to fight non-small cell lung cancer.
- ANP1: A promising therapy involving the transplant of allogeneic auditory neuron progenitor cells to combat hearing loss.
- PNC1: An innovative approach using allogeneic photoreceptor cell transplants aimed at treating vision loss.
Lineage Cell Therapeutics is committed to addressing large unmet medical needs through its cutting-edge technologies. The company's clinical-stage programs are supported by a premier collection of pluripotent cell assets, positioning it at the forefront of regenerative medicine.
Recent achievements include significant progress in clinical trials, strategic partnerships, and advancements in their product development pipeline. Financially, the company remains poised for growth with a clear focus on expanding its therapeutic offerings and enhancing shareholder value.
Stay informed with the latest updates and developments at Lineage Cell Therapeutics as they continue to advance their mission of transforming the treatment landscape for degenerative diseases.
Lineage Cell Therapeutics (NYSE: LCTX) has initiated the DOSED clinical study to evaluate a novel delivery device for OPC1, their investigational stem cell-derived transplant for spinal cord injury (SCI). The study will assess the safety and utility of the Manual Inject Parenchymal Spinal Delivery System (MI PSD System) for delivering OPC1 to injury sites.
The DOSED study will include both subacute (21-42 days post-injury) and chronic (1-5 years post-injury) SCI patients, marking the first time OPC1 will be tested in chronic cases. OPC1 has already demonstrated a strong safety profile in two previous clinical trials: a five-patient Phase 1 safety trial in acute thoracic SCI with 13+ years of follow-up, and a 25-patient Phase 1/2a trial in subacute cervical SCI with 7+ years of follow-up.
The new delivery system allows administration over several minutes without interrupting patient ventilation and is compatible with a new immediate-use formulation of OPC1. The first study site will be UC San Diego Health.
Lineage Cell Therapeutics (NYSE American and TASE: LCTX), a clinical-stage biotechnology company focused on developing allogeneic cell therapies for neurological conditions, has announced its participation in the upcoming Oppenheimer 35th Annual Healthcare Lifesciences Conference.
The company's CEO, Brian M. Culley, is scheduled to present on February 11, 2025, at 12:40pm ET. The conference will be held virtually from February 11-12, 2025. Interested parties will be able to access a replay of the presentation through the Events and Presentations section of Lineage's website, with additional video content available on the company's Media page.
Lineage Cell Therapeutics (NYSE: LCTX) has completed the second tranche of its previously announced registered direct offering, receiving an additional $6 million in gross proceeds. This follows the first tranche closure in November 2024, which brought in $24 million. The total gross proceeds received now stand at $30 million.
The company could receive up to an additional $36 million upon full exercise of OpRegen® clinical milestone-linked warrants. The second tranche involved issuing 7,894,737 common shares with accompanying warrants to Broadwood Partners at $0.76 per share. The warrants are exercisable at $0.91 per share starting May 21, 2025, expiring on May 21, 2028, or 90 days after announcing intent to advance OpRegen into a phase 2 or 3 clinical trial.
Lineage Cell Therapeutics (NYSE American and TASE: LCTX), a clinical-stage biotech firm developing allogeneic cell therapies, has published a letter to shareholders detailing recent achievements and its 2025 outlook. Lineage specializes in cell transplants, using mature, differentiated cells to replace lost or dysfunctional cells in conditions like dry age-related macular degeneration (dry-AMD). Their lead program, OpRegen, is in a Phase 2a trial in partnership with Roche and Genentech.
Lineage's financing strategy has secured $24 million in gross proceeds with an additional $6 million expected, extending their operational runway into Q1 2027. They have also issued warrants for up to $36 million, contingent on OpRegen’s advancement. The company aims to demonstrate scalable manufacturing capabilities, aspiring to produce thousands of doses from a single donor.
Looking ahead, Lineage plans to support OpRegen’s development while advancing its other programs, including OPC1 for spinal cord injuries and ReSonance™ for hearing loss. The company emphasizes its potential for long-term value creation through its unique cell transplant approach.
Lineage Cell Therapeutics (LCTX) announced the first closing of a registered direct offering of up to $66 million. The company issued 31,578,951 common shares and warrants at $0.76 per share to healthcare-focused institutional investors, receiving $24 million in gross proceeds. An additional $6 million is expected from Broadwood Partners pending shareholder approval. The warrants, exercisable at $0.91 per share, could provide up to $36 million in additional proceeds if fully exercised. The funds will be used for working capital, research and development, and capital expenditures.
Lineage Cell Therapeutics (NYSE: LCTX) has announced a registered direct offering of up to $66 million through the sale of 39,473,688 common shares and warrants. The offering includes $30 million upfront ($24 million from institutional investors and $6 million from Broadwood Partners) at $0.76 per share-warrant combination. Additional proceeds of up to $36 million may come from warrant exercises at $0.91 per share. The warrants are exercisable after six months and expire within three years or 90 days after OpRegen's Phase 2/3 trial announcement. The offering to institutional investors should close around November 21, 2024, while Broadwood's portion requires shareholder approval.
Lineage Cell Therapeutics (LCTX) reported Q3 2024 financial results with revenues of $3.8 million, up from $1.2 million in Q3 2023. The company posted a net loss of $3.0 million ($0.02 per share), improved from $7.1 million loss year-over-year. Operating expenses decreased to $7.6 million from $7.9 million. Cash position of $32.7 million is expected to fund operations into Q1 2026.
Key highlights include OpRegen receiving RMAT designation from FDA, continued collaboration with Roche/Genentech, and presentation of ReSonance preclinical results at the Inner Ear Biology Workshop.
Lineage Cell Therapeutics (NYSE American and TASE: LCTX) has scheduled its third quarter 2024 financial results announcement and business update for November 14, 2024, after U.S. market close. The company will host a conference call and webcast at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time on the same day. Investors can join via phone at (800) 715-9871 or through the company's website. A replay will be available online for 30 days and by phone until November 21, 2024, using conference ID 2238934.
Lineage Cell Therapeutics (NYSE American and TASE: LCTX), a clinical-stage biotechnology company focused on developing allogeneic cell therapies, has announced its participation in the Maxim Group 2024 Virtual Healthcare Summit. The company's CEO, Brian M. Culley, will be featured in a fireside chat hosted by Jason McCarthy, Ph.D., Senior Managing Director and Head of Biotechnology Research at Maxim Group.
The fireside chat is scheduled for Tuesday, October 15, 2024, at 11:00 a.m. ET. It will be available for viewing by registered conference attendees. This event provides an opportunity for Lineage Cell Therapeutics to showcase its progress and discuss its innovative approach to addressing unmet medical needs through allogeneic cell therapies.
Lineage Cell Therapeutics (NYSE American and TASE: LCTX) announced that CEO Brian M. Culley will present at the International Society for Stem Cell Research (ISSCR) 2024 Copenhagen International Symposium. Culley will participate in a panel on "Clinical Trial Updates: PSC-Derived Therapies of the Eye" on October 2nd, 2024. The symposium, held from October 2-4, 2024, focuses on PSC-Derived Cell Therapies.
The presentation will feature OpRegen® (RG6501), a suspension of human allogeneic retinal pigment epithelial (RPE) cells being developed to treat geographic atrophy (GA) secondary to age-related macular degeneration (AMD). OpRegen is currently in a Phase 2a clinical study and is being developed in collaboration with Roche and Genentech. The presentation will be available on Lineage's website after the panel.
FAQ
What is the current stock price of Lineage Cell The (LCTX)?
What is the market cap of Lineage Cell The (LCTX)?
What does Lineage Cell Therapeutics, Inc. specialize in?
What are the main product candidates of Lineage Cell Therapeutics?
What is OpRegen?
How does Lineage Cell Therapeutics utilize pluripotent cells?
What is OPC1 designed to treat?
What type of cancer is VAC2 targeting?
What recent achievements has Lineage Cell Therapeutics made?
What is ANP1?
What is the financial outlook of Lineage Cell Therapeutics?
Where can I find the latest updates on Lineage Cell Therapeutics?
